Emerging Signatures of Hematological Malignancies from Gene Expression and Transcription Factor-Gene Regulations DOI Open Access
Daniele Dall’Olio, Federico Magnani, Francesco Casadei

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(24), С. 13588 - 13588

Опубликована: Дек. 19, 2024

Hematological malignancies are a diverse group of cancers developing in the peripheral blood, bone marrow or lymphatic system. Due to their heterogeneity, identification novel and advanced molecular signatures is essential for enhancing characterization facilitate its translation new pharmaceutical solutions eventually clinical applications. In this study, we collected publicly available microarray data more than five thousand subjects, across thirteen hematological malignancies. Using PANDA estimate gene regulatory networks (GRNs), performed hierarchical clustering network analysis explore transcription factor (TF) interactions implications on biological pathways. Our findings reveal distinct patterns among leukemias lymphomas, with notable differences TF expression profiles. Gene Set Enrichment Analysis (GSEA) identified 57 significantly enriched KEGG pathways, highlighting both common unique processes HMs. We also potential drug targets within these emphasizing role TFs such as CEBPB NFE2L1 disease pathophysiology. comprehensive enhances understanding landscape HMs suggests avenues targeted therapeutic strategies. These motivate adoption networks, combined modern biotechnological possibilities, insightful pan-cancer exploratory studies.

Язык: Английский

Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy DOI

Rajeshwari Meli,

Osman Aksoy, Sonia Vallet

и другие.

Expert Opinion on Therapeutic Targets, Год журнала: 2025, Номер unknown

Опубликована: Март 23, 2025

Introduction Transcription factors (TFs) are master regulators of cellular function and orchestrate diverse signaling pathways processes. Acting as convergence points pathways, they integrate extracellular stimuli with intracellular responses to regulate cell functions. Dysregulation TFs drives tumorigenesis including proliferation, drug resistance, immune evasion multiple myeloma (MM), the second most-common hematologic malignancy.

Язык: Английский

Процитировано

0
Emerging Signatures of Hematological Malignancies from Gene Expression and Transcription Factor-Gene Regulations DOI Open Access
Daniele Dall’Olio, Federico Magnani, Francesco Casadei

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(24), С. 13588 - 13588

Опубликована: Дек. 19, 2024

Hematological malignancies are a diverse group of cancers developing in the peripheral blood, bone marrow or lymphatic system. Due to their heterogeneity, identification novel and advanced molecular signatures is essential for enhancing characterization facilitate its translation new pharmaceutical solutions eventually clinical applications. In this study, we collected publicly available microarray data more than five thousand subjects, across thirteen hematological malignancies. Using PANDA estimate gene regulatory networks (GRNs), performed hierarchical clustering network analysis explore transcription factor (TF) interactions implications on biological pathways. Our findings reveal distinct patterns among leukemias lymphomas, with notable differences TF expression profiles. Gene Set Enrichment Analysis (GSEA) identified 57 significantly enriched KEGG pathways, highlighting both common unique processes HMs. We also potential drug targets within these emphasizing role TFs such as CEBPB NFE2L1 disease pathophysiology. comprehensive enhances understanding landscape HMs suggests avenues targeted therapeutic strategies. These motivate adoption networks, combined modern biotechnological possibilities, insightful pan-cancer exploratory studies.

Язык: Английский

Процитировано

0